Trending

Transversal Categories

2nd International Translational and Regenerative Medicine Conference

2nd International Translational and Regenerative Medicine Conference

ITMC-2019 Conference Valencia, Spain

X

2nd International Translational and Regenerative Medicine Conference

https://pharmaphorum.com/events/international-translational-regenerative-medicine-conference/

GSK cuts 650 jobs in the US

GSK cuts 650 jobs in the US

GlaxoSmithKline moves ahead with its planed cost saving strategy and cuts 650 jobs in North Carolina, according to

X

GSK cuts 650 jobs in the US

https://pharmaphorum.com/news/glaxosmithkline-cuts-650-jobs/

Novartis sells parts of Sandoz for $1bn

Novartis sells parts of Sandoz for $1bn

After disappointing sales, Novartis trades in the Sandoz US dermatology business and generic oral solids portfolio to Aurobindo

X

Novartis sells parts of Sandoz for $1bn

https://pharmaphorum.com/news/novartis-sells-sandoz-parts/

UK’s drug supply contingency plan for hard Brexit

UK’s drug supply contingency plan for hard Brexit

The UK government has issued several documents to help businesses in planning for the eventuality of a no-deal

X

UK’s drug supply contingency plan for hard Brexit

https://pharmaphorum.com/views-analysis-market-access/hard-brexit-uk-drug-supply-contingency-plan/

Ipsen appoints new general manager for the UK & Ireland

Ipsen appoints new general manager for the UK & Ireland

The French pharma company appointed a new general manager for its UK and Ireland office, Asad Mohsin Ali,

X

Ipsen appoints new general manager for the UK & Ireland

https://pharmaphorum.com/news/ipsen-appoints-new-general-manager/

Sanofi’s rare disease drug Cablivi approved in the EU

Sanofi’s rare disease drug Cablivi approved in the EU

The European Commission has approved Sanofi’s Cablivi, the first treatment for patients with the rare blood-clotting disorder, acquired

X

Sanofi’s rare disease drug Cablivi approved in the EU

https://pharmaphorum.com/news/sanofi-cablivi-approved-europe/

FDA approves Merck’s Delstrigo and Pifeltro for HIV treatment

FDA approves Merck’s Delstrigo and Pifeltro for HIV treatment

Merck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA)

X

FDA approves Merck’s Delstrigo and Pifeltro for HIV treatment

https://pharmaphorum.com/news/fda-approves-mercks-hiv-treatment/

Pfizer axes development of Duchenne muscular dystrophy antibody

Pfizer axes development of Duchenne muscular dystrophy antibody

Pfizer has axed trials of its domagrozumab antibody for Duchenne muscular dystrophy (DMD), after it failed against efficacy

X

Pfizer axes development of Duchenne muscular dystrophy antibody

https://pharmaphorum.com/news/duchenne-trials-axed-pfizer-dmd/

AstraZeneca improves diabetes pen to maintain its market share

AstraZeneca improves diabetes pen to maintain its market share

The European Commission (EC) has approved AstraZeneca’s Bydureon BCise, a new weekly formulation of established GLP-1 diabetes drug

X

AstraZeneca improves diabetes pen to maintain its market share

https://pharmaphorum.com/news/astrazeneca-improves-diabetes-pen-to-maintain-its-market-share/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com